Trials / Completed
CompletedNCT00752219
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ceftazidime/NXL104 + metronidazole | IV TID |
| DRUG | meropenem | IV TID |
Timeline
- Start date
- 2009-03-31
- Primary completion
- 2009-11-30
- Completion
- 2009-12-31
- First posted
- 2008-09-15
- Last updated
- 2018-07-03
- Results posted
- 2018-07-03
Locations
45 sites across 8 countries: United States, Bulgaria, France, India, Lebanon, Poland, Romania, Russia
Source: ClinicalTrials.gov record NCT00752219. Inclusion in this directory is not an endorsement.